United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $541.55, for a total transaction of $4,494,865.00. Following the completion of the transaction, the executive vice president owned 45,172 shares in the company, valued at approximately $24,462,896.60. This represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

United Therapeutics Trading Down 2.7%

United Therapeutics stock traded down $14.88 during trading on Thursday, hitting $536.59. The company had a trading volume of 1,645,718 shares, compared to its average volume of 488,354. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The company’s 50 day simple moving average is $565.95 and its 200-day simple moving average is $522.96. The stock has a market cap of $22.78 billion, a price-to-earnings ratio of 19.81, a price-to-earnings-growth ratio of 1.79 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same quarter last year, the company earned $6.63 earnings per share. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. As a group, analysts forecast that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP grew its stake in United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares in the last quarter. Darwin Global Management Ltd. acquired a new stake in United Therapeutics in the 3rd quarter valued at about $317,617,000. Norges Bank purchased a new position in shares of United Therapeutics in the 4th quarter valued at about $293,418,000. Avoro Capital Advisors LLC boosted its stake in shares of United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after buying an additional 383,838 shares during the period. Finally, Janus Henderson Group PLC grew its position in shares of United Therapeutics by 75.1% during the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after buying an additional 341,383 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Bank of America increased their target price on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 31st. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday, June 11th. Raymond James Financial started coverage on shares of United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target on the stock. Oppenheimer raised their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Finally, TD Cowen restated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.